Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849767 | 0.92 | TRPV1 (0.59) | TRPV1FAAHMKNK1 | |
| SCHEMBL4866606 | 0.90 | TRPV1 (0.55) | TRPV1FAAHMKNK1 | |
| SCHEMBL4864601 | 0.89 | MKNK1 (0.57) | FAAHMKNK1 | |
| SCHEMBL4871319 | 0.88 | MKNK1 (0.55) | TRPV1FAAHMKNK1 | |
| SCHEMBL4872158 | 0.87 | FAAH (0.73) | TRPV1FAAHMKNK1 | |
| SCHEMBL4870103 | 0.85 | FAAH (0.53) | TRPV1FAAHMKNK1 | |
| SCHEMBL14086113 | 0.84 | TRPV1 (0.55) | TRPV1FAAH | |
| SCHEMBL3933677 | 0.83 | FAAH (0.77) | TRPV1FAAHMKNK1 | |
| SCHEMBL4872328 | 0.83 | MKNK1 (0.50) | TRPV1FAAHMKNK1 | |
| SCHEMBL6001408 | 0.82 | MKNK1 (0.52) | TRPV1FAAHMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713807-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005070929-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-08-04 | — | — | WO | claimed |
| US-20050165032-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | claimed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2006118598-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1713807-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1697361-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | Renovis, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060128710-A1 | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBOTT LABORATORIES | 2006-06-15 | — | — | US | disclosed |
| US-20050277643-A1 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | EVOTEC AG (DE) | 2005-12-15 | — | — | US | disclosed |
| US-20050215572-A1 | N-(4-tert-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yl]-amine; antiinflammatory agents treating pain, inflammation, traumatic injury, arthritis, Parkinson's disease, Alzheimer's disease, stroke, asthma, myocardial infarction | EVOTEC AG (DE) | 2005-09-29 | — | — | US | disclosed |
| WO-2005070929-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165032-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2005066171-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128710-A1 | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof | OPRL1, AVPR1A, AVPR2 | TRPV1 5/4885FAAH 480/4885MKNK1 4146/4885 |
| US-20050165032-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885FAAH 425/4885MKNK1 1672/4885 |
| US-20050215572-A1 | N-(4-tert-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yl]-amine; antiinflammatory agents treating pain, inflammation, traumatic injury, arthritis, Parkinson's disease, Alzheimer's disease, stroke, asthma, myocardial infarction | PARK7, PTGIS, PTGES | TRPV1 224/4885FAAH 207/4885MKNK1 1430/4885 |
| US-20050277643-A1 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | TRPV1, TRPV3, TRPA1 | TRPV1 1/4885FAAH 334/4885MKNK1 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.